Virginia Gov. Glenn Youngkin vetoed legislation late Monday that would have established an advisory board to better manage the state’s prescription drug costs. Other states have launched such advisory boards in recent months as part of growing efforts to set ceiling prices for certain high-cost treatments.
Youngkin said he vetoed the bill because the legislation didn’t take individual patients’ needs into consideration. The legislation would have allowed a Virginia prescription drug advisory board to place price caps on the state’s payments to pharma companies, allowing for up to 12 caps per year between 2025 and 2028.
“The proposed authority granted to the Prescription Drug Affordability Board (PDAB) would allow medication availability to be determined based solely on cost considerations rather than accounting for the expert opinions of health care professionals and the unique medical needs of individual patients,” Youngkin said in a Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
